Indacaterol/mometasone
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.[1]
| Combination of | |
|---|---|
| Indacaterol | Beta-2 adrenergic receptor agonist |
| Mometasone | Corticosteroid |
| Clinical data | |
| Trade names | Atectura Breezhaler, Bemrist Breezhaler |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[1] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[1]
Indacaterol/mometasone was approved for medical use in the European Union in May 2020.[1]
References
- "Atectura Breezhaler EPAR". European Medicines Agency (EMA). 24 March 2020. Retrieved 23 June 2020.
External links
- "Indacaterol mixture with mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
| Adrenergics, inhalants |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoids |
| ||||||||
| Anticholinergics/ muscarinic antagonist | |||||||||
| Mast cell stabilizers | |||||||||
| Xanthines | |||||||||
| Eicosanoid inhibition |
| ||||||||
| Others/unknown | |||||||||
| Combination products |
| ||||||||
| |||||||||
| GR |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| |||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.